Copycats earning big PBS bucks

Samsung Bioepis' Brenzys has been crowned the top-earning PBS listed biosimilar brand, however, biosimilars of AbbVie's Humira combined cost the government more overall.

According to the latest PBS Expenditure and Prescriptions report for the 2022-23 financial year, Brenzys - a biosimilar of Pfizer's Enbrel - cost the government $41.8 million over the reported period.

Meanwhile, the cost of five biosimilars of AbbVie's Humira combined came in at over $47.2 million.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here